布拉酵母菌益生菌治疗后发生的与导管相关的酿酒酵母菌菌血症：一名重症监护病房儿童病例及文献综述
Catheter-related Saccharomyces cerevisiae Fungemia Following Saccharomyces boulardii Probiotic Treatment: In a child in intensive care unit and review of the literature.
作者信息
Atıcı Serkan, Soysal Ahmet, Karadeniz Cerit Kıvılcım, Yılmaz Şerife, Aksu Burak, Kıyan Gürsu, Bakır Mustafa
机构信息
Department of Pediatrics and Division of Pediatric Infectious Diseases, Medical School, Marmara University, Istanbul, Turkey.
Department of Pediatric Surgery, Medical School, Marmara University, Istanbul, Turkey.
出版信息
Med Mycol Case Rep. 2017 Feb 22;15:33-35. doi: 10.1016/j.mmcr.2017.02.002. eCollection 2017 Mar.
Abstract
Although is usually a non-pathogenic fungus, in rare occasions it can cause invasive infection in children. We present the case of an 8-year-old patient in pediatric surgical intensive care unit who developed fungemia following probiotic treatment containing . Caspofungin was not effective in this case and he was treated with amphotericin B. We want to emphasize that physicians should be careful about probiotic usage in critically ill patients.
摘要
虽然通常是一种非致病性真菌，但在极少数情况下，它可导致儿童发生侵袭性感染。我们报告一例8岁患儿的病例，该患儿在儿科外科重症监护病房接受含有的益生菌治疗后发生了真菌血症。在该病例中，卡泊芬净无效，他接受了两性霉素B治疗。我们想强调的是，医生在危重症患者使用益生菌时应谨慎。
相似文献
1
Catheter-related Saccharomyces cerevisiae Fungemia Following Saccharomyces boulardii Probiotic Treatment: In a child in intensive care unit and review of the literature.布拉酵母菌益生菌治疗后发生的与导管相关的酿酒酵母菌菌血症：一名重症监护病房儿童病例及文献综述
Med Mycol Case Rep. 2017 Feb 22;15:33-35. doi: 10.1016/j.mmcr.2017.02.002. eCollection 2017 Mar.
2
Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic.接受布拉氏酵母菌散（Saccharomyces boulardii probiotic）治疗的住院患者中念珠菌属酵母菌血症的发生率。
Mycoses. 2021 Dec;64(12):1521-1526. doi: 10.1111/myc.13375. Epub 2021 Oct 9.
3
Saccharomyces cerevisiae fungemia due to an unexpected source in the pediatric intensive care unit.儿科重症监护病房中由意外来源引起的酿酒酵母菌血症。
Turk J Pediatr. 2022;64(1):138-141. doi: 10.24953/turkjped.2020.1668.
4
Saccharomyces cerevisiae fungemia after probiotic treatment in an intensive care unit patient.重症监护病房患者在接受益生菌治疗后发生酵母菌血症。
J Mycol Med. 2018 Mar;28(1):218-221. doi: 10.1016/j.mycmed.2017.09.003. Epub 2017 Nov 11.
5
Saccharomyces cerevisiae fungemia: Risk factors, outcome and links with S. boulardii-containing probiotic administration.酿酒酵母菌血症：危险因素、结局及与含布拉氏酵母菌的益生菌制剂应用的关系。
Infect Dis Now. 2021 May;51(3):293-295. doi: 10.1016/j.idnow.2020.12.003. Epub 2020 Dec 31.
6
[Saccharomyces cerevisiae fungemia in an elderly patient following probiotic treatment].[一名老年患者在接受益生菌治疗后发生酿酒酵母菌血症]
Mikrobiyol Bul. 2014 Apr;48(2):351-5. doi: 10.5578/mb.6970.
7
Epidemiology of Saccharomyces fungemia: A systematic review.酵母菌菌血症的流行病学：系统评价。
Med Mycol. 2023 Feb 3;61(2). doi: 10.1093/mmy/myad014.
8
fungemia in a critically ill patient with acute cholangitis and long term probiotic use.一名患有急性胆管炎且长期使用益生菌的重症患者发生真菌血症。
Med Mycol Case Rep. 2018 Nov 12;23:23-25. doi: 10.1016/j.mmcr.2018.11.003. eCollection 2019 Mar.
9
Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient.老年患者应用布拉氏酵母菌散（Saccharomyces cerevisiae var. boulardii）益生菌治疗后发生真菌血症。
Rev Argent Microbiol. 2020 Jan-Mar;52(1):27-30. doi: 10.1016/j.ram.2019.04.002. Epub 2019 Jun 28.
10
Saccharomyces cerevisiae var. boulardii fungemia following probiotic treatment.益生菌治疗后出现的布拉酵母菌血症
Med Mycol Case Rep. 2017 Jul 25;18:15-17. doi: 10.1016/j.mmcr.2017.07.007. eCollection 2017 Dec.
引用本文的文献
1
In Silico Evaluation of Acalypha indica Phytochemicals as Potential Antifungal Agents Targeting Saccharomyces cerevisiae Lanosterol 14-Alpha Demethylase.对印度铁苋菜植物化学物质作为靶向酿酒酵母羊毛甾醇14-α-去甲基酶的潜在抗真菌剂的计算机模拟评估。
Cell Biochem Biophys. 2025 Jul 22. doi: 10.1007/s12013-025-01836-w.
2
Typing of clinical and reference strains of Saccharomyces cerevisiae using pulsed-field gel electrophoresis and MALDI-TOF MS.使用脉冲场凝胶电泳和基质辅助激光解吸电离飞行时间质谱对酿酒酵母临床菌株和参考菌株进行分型。
Sci Rep. 2025 May 16;15(1):17053. doi: 10.1038/s41598-025-01645-4.
3
Unlocking the Potential of Probiotics: A Comprehensive Review on Research, Production, and Regulation of Probiotics.解锁益生菌的潜力：益生菌研究、生产和监管的综合综述。
Probiotics Antimicrob Proteins. 2024 Oct;16(5):1687-1723. doi: 10.1007/s12602-024-10247-x. Epub 2024 Mar 28.
4
Accounting for the health risk of probiotics.考虑益生菌的健康风险。
Heliyon. 2024 Mar 10;10(6):e27908. doi: 10.1016/j.heliyon.2024.e27908. eCollection 2024 Mar 30.
5
Species distribution and antifungal susceptibility profiles of yeasts isolated from onychomycosis: a cross-sectional study with insights into emerging species.从甲真菌病中分离的酵母菌的物种分布和抗真菌药敏谱：一项具有新兴物种见解的横断面研究。
Antonie Van Leeuwenhoek. 2023 Dec 28;117(1):6. doi: 10.1007/s10482-023-01914-0.
6
Nutritional Management of Oncological Symptoms: A Comprehensive Review.肿瘤症状的营养管理：全面综述
Nutrients. 2023 Dec 11;15(24):5068. doi: 10.3390/nu15245068.
7
The Optimal Time for Initiating Probiotics for Preterm and Very-Low-Birth-Weight Infants: A 10-Year Experience in a Single Neonatal Intensive Care Unit.为早产儿和极低出生体重儿开始使用益生菌的最佳时机：在单一新生儿重症监护病房的10年经验
Pediatr Gastroenterol Hepatol Nutr. 2023 May;26(3):146-155. doi: 10.5223/pghn.2023.26.3.146. Epub 2023 May 11.
8
A case of bloodstream co-infection of Saccharomyces cerevisiae and Candida glabrata while using micafungin.米卡芬净使用过程中血液念珠菌合并感染酵母菌和光滑念珠菌 1 例
BMC Infect Dis. 2023 May 16;23(1):329. doi: 10.1186/s12879-023-08287-9.
9
SARS-CoV-2 Post-Infection and Sepsis by : A Fatal Case Report-Focus on Fungal Susceptibility and Potential Virulence Attributes.严重急性呼吸综合征冠状病毒2感染后与脓毒症：一例死亡病例报告——聚焦真菌易感性及潜在毒力特征
Trop Med Infect Dis. 2023 Feb 2;8(2):99. doi: 10.3390/tropicalmed8020099.
10
Invasive Infections Associated with the Use of Probiotics in Children: A Systematic Review.儿童使用益生菌相关的侵袭性感染：一项系统评价
Children (Basel). 2021 Oct 16;8(10):924. doi: 10.3390/children8100924.
本文引用的文献
1
Draft Genome Sequence of the Probiotic Yeast Saccharomyces cerevisiae var. boulardii Strain ATCC MYA-796.益生菌酿酒酵母变种布拉迪酵母菌株ATCC MYA - 796的基因组序列草图
Genome Announc. 2014 Dec 18;2(6):e01345-14. doi: 10.1128/genomeA.01345-14.
2
Saccharomyces boulardii fungemia caused by treatment with a probioticum.因使用益生菌治疗导致的布拉氏酵母菌菌血症。
BMJ Case Rep. 2012 Mar 27;2012:bcr0620114412. doi: 10.1136/bcr.06.2011.4412.
3
Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.布拉氏酵母菌（Saccharomyces boulardii）用于预防和治疗胃肠道疾病的疗效和安全性。
Therap Adv Gastroenterol. 2012 Mar;5(2):111-25. doi: 10.1177/1756283X11428502.
4
Review article: yeast as probiotics -- Saccharomyces boulardii.综述文章：作为益生菌的酵母——布拉氏酵母菌。
Aliment Pharmacol Ther. 2007 Sep 15;26(6):767-78. doi: 10.1111/j.1365-2036.2007.03442.x.
5
Catheter-related fungemia caused by Saccharomyces cerevisiae in a newborn.一名新生儿由酿酒酵母引起的导管相关真菌血症。
Pediatr Infect Dis J. 2005 Dec;24(12):1125. doi: 10.1097/01.inf.0000189984.51944.cd.
6
Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration.酿酒酵母菌血症：布拉氏酵母菌益生菌给药的一种不良反应。
Clin Infect Dis. 2005 Jun 1;40(11):1635-7. doi: 10.1086/429926. Epub 2005 Apr 25.
7
Saccharomyces cerevisiae fungemia: an emerging infectious disease.酿酒酵母菌血症：一种新出现的传染病。
Clin Infect Dis. 2005 Jun 1;40(11):1625-34. doi: 10.1086/429916. Epub 2005 Apr 25.
8
Methaemoglobinaemia with concurrent blood isolation of Saccharomyces and Candida.伴有同时从血液中分离出酿酒酵母和念珠菌的高铁血红蛋白血症。
Arch Dis Child Fetal Neonatal Ed. 2003 Sep;88(5):F446. doi: 10.1136/fn.88.5.f446.
9
[Verrucous endocarditis secondary to Saccharomyces cerevisiae. A case report].[酿酒酵母继发疣状心内膜炎。病例报告]
Rev Med Chil. 2002 Oct;130(10):1165-9.
10
Clustering of Saccharomyces boulardii strains within the species S. cerevisiae using molecular typing techniques.使用分子分型技术对酿酒酵母属内的布拉氏酵母菌菌株进行聚类分析。
J Appl Microbiol. 2002;93(4):521-30. doi: 10.1046/j.1365-2672.2002.01710.x.
Zotero 插件